Table 3.

Anthropometric measures and laboratory values at baseline and after 12 months.

	n	Obese study population, baseline, median (range)	n	Obese study population, follow-up, median (range)	P
BMI
All participants	39	28.48 (20.9–42.7)
Patients with paired follow-up data	36	28.13 (20.9–42.7)	36	27.79 (19.2–44.9)	0.925
BMI percentile
All participants	39	99.1 (90.7–99.9)
Patients with paired follow-up data	36	98.95 (90.7–99.9)	36	98.55 (81.3–99.9)	0.003
BMI-SDS
All participants	39	2.36 (1.33–3.58)
Patients with paired follow-up data	36	2.31 (1.33–3.58)	36	2.25 (0.90–3.68)	0.028
WHtR
All participants	39	0.61 (0.51–0.74)
Patients with paired follow-up data	33	0.60 (0.51–0.73)	33	0.60 (0.47–0.77)	0.914
Triglyceride
All participants	39	80 mg/dL (25–317)
Patients with paired follow-up data	36	81 mg/dL (25–317)	36	61 mg/dL (22–328)	0.020
Total cholesterol
All participants	39	177 mg/dL (108–289)
Patients with paired follow-up data	36	180 mg/dL (108–289)	36	166 mg/dL (108–265)	0.090
LDL cholesterol
All participants	39	110 mg/dL (44–225)
Patients with paired follow-up data	36	110 mg/dL (44–225)	36	104 mg/dL (48–207)
Fasting glucose
All participants	39	84 mg/dL (69–107)
Patients with paired follow-up data	36	84 mg/dL (69–107)	36	81 mg/dL (67–97)	0.002
HOMA index
All participants	37	3.2 (1.1–7.4)	31	2.4 (0.3–7.1)
Patients with paired follow-up data	29	3.2 (1.1–7.4)	29	2.3 (0.3–7.1)	0.091
Transient elastography
All participants	28	5.9 kPa (3.4–8.3)	21	4.5 kPa (2.4–9.6)
Patients with paired follow-up data	18	5.0 kPa (3.4–8.3)	18	4.4 kPa (2.4–9.6)	0.076
Enhanced liver fibrosis (ELF) test
All participants	33	9.0 (7.87–9.60)	27	8.51 (7.15–9.55)
Patients with paired follow-up data	25	8.9 (7.87–9.60)	25	8.51 (7.15–9.55)	0.02

BMI: body mass index; WHtR: waist-to-height ratio; HOMA: homeostasis model assessment.